Table 1.
Summary of baseline characteristics
| Risedronate | |||
|---|---|---|---|
| 5 mg IR daily | 35 mg DR FB weekly | 35 mg DR BB weekly | |
| (N = 307) | (N = 307) | (N = 308) | |
| Age (years), mean (SD) | 65.3 (7.4) | 65.8 (7.4) | 66.0 (7.5) |
| Years since menopause, mean (SD) | 17.5 (8.6) | 18.2 (8.0) | 18.8 (8.5) |
| Years since last menses (n [%]) | |||
| 5 to 10 years | 78 (25.4) | 60 (19.5) | 62 (20.1) |
| More than 10 years | 229 (74.6) | 247 (80.5) | 246 (79.9) |
| Race (n [%]) | |||
| White | 306 (99.7) | 305 (99.3) | 306 (99.4) |
| Asian (Oriental) | 1 (0.3) | 1 (0.3) | 0 (0.0) |
| Multi-racial | 0 (0.0) | 1 (0.3) | 2 (0.6) |
| Prevalent vertebral fracture (n [%]) | 70 (24.1)a | 81 (28.2)a | 87 (29.1)a |
| Standardizedb lumbar spine bone BMD (mg/cm2), mean (SD) | 762 (60) | 763 (68) | 763 (73) |
| Lumbar spine BMD T-score, mean (SD) | −3.12 (0.52) | −3.11 (0.59) | −3.11 (0.56) |
| Standardizedb total proximal femur BMD (mg/cm2), mean (SD) | 591 (178) | 593 (162) | 593 (171) |
| Proximal femur BMD T-score, mean (SD) | −2.96 (1.44) | −2.95 (1.32) | −2.94 (1.39) |
| Urinary NTX/creatinine (nmol BCE/mmol creatinine), mean (SD) | 76.1 (33.0) | 74.8 (36.1) | 72.7 (33.7) |
| Serum CTX (ng/mL). mean (SD) | 0.643 (0.272) | 0.642 (0.288) | 0.671 (0.849) |
| Serum BAP (μg/L), mean (SD) | 28.6 (9.6) | 27.3 (8.4) | 27.5 (8.4) |
BAP bone-specific alkaline phosphatase, BB before breakfast, BMD bone mineral density, CTX type-1 collagen cross-linked C-telopeptide, DR delayed-release, FB following breakfast, IR immediate-release, NTX type-1 collagen cross-linked N-telopeptide corrected for creatinine
aPercent is based upon the number of subjects with known vertebral fracture status (5 mg IR daily group, 291; 35 mg DRFB weekly group, 287; 35 mg DRBB weekly group, 299)
bAdjusted to account for machine type [10]